Triptorelin: all 102 studies that test it

Page 1 of 2. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)RecruitingNCT07816562Phase 3
• Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating EndometriosisRecruitingNCT07696351Phase 4
• Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingNCT07455903Phase 2
• COMPASS - COpenhagen MenoPAuSe StudyRecruitingNCT07254429Phase 2
• Intranasal Nafarelin For Triggering Oocyte MaturationRecruitingNCT06763926Phase 4
• Effect GnRH Agonist Administration in Endometriosis Cyst PatientsRecruitingNCT06525155Phase 3
• Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With CancerRecruitingNCT06513962Phase 3
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingNCT06282588Phase 2/3
• Dose Escalation For INtraprostatic LEsionsRecruitingNCT05851547Phase 2
• Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624RecruitingNCT05781217Phase 3
• Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcerRecruitingNCT05557604Phase 2
• Use of GnRHa During Chemotherapy for Fertility ProtectionRecruitingNCT05328258Phase 3
• SRT Versus SRT+ADT in Prostate CancerRecruitingNCT05019846Phase 3
• DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte MaturationRecruitingNCT04616729Phase 1/2
• GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FETRecruitingNCT04064840Phase 3
• GnRHa for Luteal Phase Support in GnRH Antagonist Protocol CyclesRecruitingNCT02312089Phase 4
• GnRHa for Luteal Phase Support in Long GnRHa Protocol CyclesRecruitingNCT02312076Phase 4
• Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateCompletedNCT05458856Phase 3Results posted
• A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.CompletedNCT05029622Phase 3Results posted
• Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.CompletedNCT04736602Phase 3Results posted
• Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian HyperstimulationCompletedNCT02342197Phase 3Results posted
• TRial on the Endocrine Activity of Neoadjuvant DegarelixCompletedNCT02005887Phase 2Results posted
• A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.CompletedNCT01753297Phase 4Results posted
• Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate CancerCompletedNCT01715129Phase 3Results posted
• GP Extended Action TriptorelinTerminatedNCT01673984Phase 4Results posted
• Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate CancerCompletedNCT01656161Phase 3Results posted
• Trial Comparing hCG Triggering Versus hCG Associated With GnRH AgonistCompletedNCT01607203Phase 4Results posted
• Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious PubertyCompletedNCT01467882Phase 3Results posted
• Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate CancerTerminatedNCT01374087Phase 2Results posted
• Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mgCompletedNCT01257425Phase 2Results posted
• Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue AdministrationCompletedNCT01161563Phase 4Results posted
• Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate CancerCompletedNCT01020448Phase 3Results posted
• Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up StudyCompletedNCT00909844Phase 3Results posted
• Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate CancerCompletedNCT00751790Phase 3Results posted
• Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02CompletedNCT00659373Phase 3Results posted
• Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious PubertyCompletedNCT00564850Phase 3Results posted
• Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast CancerTerminatedNCT00194792Phase 2Results posted
• Triptorelin for Ovary Protection in Childhood Onset LupusCompletedNCT00124514Phase 2Results posted
• Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast CancerTerminatedNCT00090844Phase 2Results posted
• Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerCompletedNCT00066690Phase 3Results posted
• Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate CancerWithdrawnNCT06795191Phase 3
• Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate CancerWithdrawnNCT06795178Phase 3
• Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst TransferCompletedNCT06581679Not applicable
• A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerCompletedNCT05896566Phase 2
• COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLESStatus unknownNCT05397795Phase 3
• Comparison of Triggers in Double Ovarian Stimulation (DuoStim).Status unknownNCT05321511Phase 4
• Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase SupportCompletedNCT05286554Phase 4
• Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerStatus unknownNCT05212857Phase 2
• Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingNCT05050084Phase 3
• Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycleCompletedNCT04846218Not applicable
• Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2
• Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer PatientsStatus unknownNCT04248621Phase 4
• Generation of Biological Samples Positive to Triptorelin for Anti-doping ControlCompletedNCT04189900Phase 1
• Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female InfertilityCompletedNCT04071574Phase 1/2
• The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian HyperstimulationStatus unknownNCT03809221Phase 4
• Follicle Size and Oocyte DevelopmentCompletedNCT03660813Not applicable
• Early Preparation With Gonadotropin- Releasing Hormon (GnRh) Agonists Injection With Frozen-Thawed Embryo Transfer?Status unknownNCT03353883Phase 2/3
• The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive TechnologiesCompletedNCT03169166Phase 4
• Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSICompletedNCT03118830Phase 4
• Luteal Phase Support in Insemination CyclesCompletedNCT03115307Phase 4
• Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ETStatus unknownNCT03071172Phase 3
• GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCTCompletedNCT03039049Phase 3
• Effects of SNP of GnRH Receptor Genes in IVF PatientsStatus unknownNCT02979886Not applicable
• Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian ResponseStatus unknownNCT02940535Not applicable
• Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for CancerStatus unknownNCT02856048Phase 2/3
• Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSSStatus unknownNCT02827656Not applicable
• Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective StudyStatus unknownNCT02825290Phase 4
• Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate CancerTerminatedNCT02749825Phase 4
• Effects of Sex Steroids on the Serotonin SystemStatus unknownNCT02715232Phase 4
• Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist ProtocolStatus unknownNCT02635607Not applicable
• GnRH Agonist as Luteal Support in FET CyclesCompletedNCT02620124Phase 4
• Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis PatientsCompletedNCT02400801Not applicable
• High-Dose Brachytherapy in Treating Patients With Prostate CancerCompletedNCT02346253Not applicable
• GnRHa Trigger in Asian Oocyte Donors- a Dose Finding StudyCompletedNCT02208986Not applicable
• GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian ResponseStatus unknownNCT02144818Not applicable
• Anti-Mullerian Hormone (AMH) as Marker of Ovarian ReserveTerminatedNCT02113553Phase 2
• MRI Substudy; Metabolic Changes Due to Iatrogenic HypogonadismCompletedNCT02102646Phase 4
• GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCTCompletedNCT02053779Phase 3
• Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation SyndromeStatus unknownNCT02022241Not applicable
• Dual Trigger to Reduce Ovarian Hyperstimulation SyndromeStatus unknownNCT02022228Not applicable
• Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS PatientsStatus unknownNCT01973842Phase 2
• Androgen Deprivation Therapy in Advanced Salivary Gland CancerCompletedNCT01969578Phase 2
• GnRH Agonist Pretreatment in Hysteroscopic MyomectomyCompletedNCT01873378Not applicable
• Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma PatientsCompletedNCT01764230Not applicable
• Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?TerminatedNCT01714648Phase 4
• Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCGCompletedNCT01638026Phase 4
• The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With EndometriosisCompletedNCT01581359Phase 4
• Endometrial Receptivity After GnRH Agonist TriggeringCompletedNCT01500863Phase 4
• Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate DaysCompletedNCT01468441Not applicable
• Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian FailureCompletedNCT01160315Phase 2/3
• Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET CyclesTerminatedNCT01007851Phase 3
• Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal WomenCompletedNCT00735852Phase 4
• Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate CancerCompletedNCT00667069Phase 3
• Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer CyclesStatus unknownNCT00542126Not applicable
• GnRH Agonist Administration in the Luteal Phase of ICSI-ET CyclesCompletedNCT00516490Not applicable
• GnRH Agonist and Intrauterine InseminationCompletedNCT00503217Phase 4
• Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)TerminatedNCT00444639Phase 2
• Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF DrugsStatus unknownNCT00415792Phase 4
• Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate CancerTerminatedNCT00415246Phase 3
• Investigation of Early Hormonotherapy Efficacy of Prostate CancerStatus unknownNCT00375687Not applicable

← Triptorelin overview